Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) closed the most recent session at $230.42, up 2.58% on the week as buyers rotated back into
Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?
Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock?
S&P Global rates only two U.S. public companies AAA, one notch above the federal government itself.
Johnson & Johnson (JNJ) Presents at Bank of America Global Healthcare Conference 2026 Transcript
JNJ bets on Tremfya and newly approved Icotyde to drive immunology growth as Stelara faces biosimilar pressure.
Darzalex and new launches fuel J&J's 17.8% oncology sales growth in Q1 as the company targets $50B in cancer sales by 2030.
Earned income disappears the moment you stop working. Dividend income keeps arriving every quarter.
Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?
Passive income separates a paycheck from a portfolio. Earned income stops when you stop working, but dividends landing quarterly do not.